Everest Medicines’ Licensing Partner Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients’ Daily Lives and Quality of Life Between Episodes

Shanghai, China - September 18, 2026 - Everest Medicines (HKEX 1952.HK, "Everest", or the "Company") announced findings from a longitudinal study describing how paroxysmal supraventricular tachycardia (PSVT) affects patients’ daily lives and quality of life in the periods between episodes. The findings are being presented in a moderated ePoster session titled “The Impact of PSVT on Patients’ Daily Life and QoL in Between Episodes” at the European Society of Cardiology (ESC) Congress 2026 on August 30, 2026, 15:15-16:00 CET, Station 6, Research Gateway, Hall A1. The news was previously released by Milestone Pharmaceuticals Inc . (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Everest Medicines has an exclusive license with Milestone to develop and commercialize etripamil nasal spray in Greater China (including Mainland China, Hong Kong, Macao and Taiwan). 

China’s National Medical Products Administration (NMPA) has approved CARDAMYST^® (etripamil) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.

PSVT is a common heart rhythm disorder in which the heart suddenly beats ver en-us Copyright 2026 EQS Group